Investor Relations
Znomics is biotechnology company using proprietary zebrafish technology to find new drugs and drug targets for complex human diseases. The company is developing a novel drug discovery methodology based on high throughput drug screening against human disease models in live zebrafish. This methodology screens against all potential drug targets in the animal and improves the speed and efficacy of finding lead compounds compared with single target screens predominantly used in the pharmaceutical industry.
Znomics' new drug discovery approach is based on its catalogued library of mutations in the zebrafish, called the ZeneMark Library. The library, the first in a vertebrate, currently contains more than 11,000 strains of fish representing mutations in more than half of the known zebrafish genes. The Company is leveraging this technology for its internal drug discovery efforts as well as making collaborative partnerships with pharmaceutical companies and universities. The Company also sells mutant fish strains to university scientists, for research purposes, obtaining rights to license new discoveries in academic laboratories.
Recent Releases
May 14, 2008
Znomics to Hold Business Strategy Conference Call May 22, 2008
Events
May 22, 2008
Znomics Business Strategy Update Conference Call
© Copyright Znomics, Inc. All rights reserved.